Guideline on good pharmacovigilance practices (GVP)

15 April 2014 EMA/876333/2011 Rev 3* (superseded version)

Guideline on good pharmacovigilance practices (GVP)

Annex I - Definitions (Rev 3)

Date for coming into effect of first version Date for coming into effect of Revision 1 Date for coming into effect of Revision 2 Draft Revision 3* finalised by the Agency in collaboration with Member States Draft Revision 3 provided to ERMS FG Draft Revision 3 adopted by Executive Director as final Date for coming into effect of Revision 3*

2 July 2012 13 December 2012

8 January 2014 12 March 2014

2 April 2014 15 April 2014 28 April 2014

*Note: Revision 3 includes the following:

- Amendments of definitions of Missing information (including its explanatory note) and Risk minimisation activity in accordance with revision 1 of GVP Module V.

This version is not valid anymore, but kept on the Agency's website for the purpose of public access to historical documents. For the valid version, please refer to the Agency's GVP webpage for the latest revision of this GVP Annex.

See websites for contact details

European Medicines Agency ema.europa.eu Heads of Medicines Agencies hma.eu

The European Medicines Agency is an agency of the European Union

? European Medicines Agency and Heads of Medicines Agencies, 2017. Reproduction is authorised provided the source is acknowledged.

Table of contents

Abuse of a medicinal product........................................................................................5 Advanced therapy medicinal product (ATMP) ..................................................................5 Adverse event (AE); synonym: Adverse experience.........................................................5 Adverse event following immunisation (AEFI) .................................................................5 Adverse reaction; synonyms: Adverse drug reaction (ADR), Suspected adverse (drug) reaction, Adverse effect, Undesirable effect ....................................................................5 Audit .........................................................................................................................5 Audit finding(s)...........................................................................................................5 Audit plan ..................................................................................................................6 Audit programme........................................................................................................6 Audit recommendation ................................................................................................6 Clinical trial ................................................................................................................6 Closed signal ..............................................................................................................6 Company core data sheet (CCDS) .................................................................................7 Company core safety information (CCSI) .......................................................................7 Compassionate use of a medicinal product .....................................................................7 Completed clinical trial ................................................................................................7 Consumer ..................................................................................................................7 Crisis ......................................................................................................................... 7 Data lock point ...........................................................................................................8 Development international birth date (DIBD)..................................................................8 Development safety update report (DSUR).....................................................................8 Direct healthcare professional communication (DHPC) .....................................................8 EU reference date; synonym: Union reference date.........................................................8 Failure to vaccinate .....................................................................................................8 Generic medicinal product............................................................................................9 Good pharmacovigilance practices (GVP) for the European Union ......................................9 Healthcare professional ...............................................................................................9 Herbal medicinal product .............................................................................................9 Homeopathic medicinal product ....................................................................................9 Identified risk .............................................................................................................9 Illegal purposes ........................................................................................................ 10 Immunological medicinal product ................................................................................ 10 Immunisation ........................................................................................................... 10 Immunisation anxiety-related reaction ........................................................................ 10 Immunisation error-related reaction ............................................................................ 11 Important identified risk and Important potential risk .................................................... 11 Important potential risk ............................................................................................. 11 Incident ................................................................................................................... 11 Individual case safety report (ICSR); synonym: Adverse (drug) reaction report ................ 12 International birth date (IBD) ..................................................................................... 12 Investigational drug .................................................................................................. 12 Investigational medicinal product................................................................................ 12 Labelling .................................................................................................................. 12

Guideline on good pharmacovigilance practices (GVP) ? Annex I (Rev 3) EMA/876333/2011 Rev 3 (superseded version)

Page 2/24

Medicinal product...................................................................................................... 12 Medicinal product derived from human blood or human plasma ...................................... 12 Minimum criteria for reporting .................................................................................... 13 Missing information ................................................................................................... 13 Misuse of a medicinal product..................................................................................... 13 Misuse of a medicinal product for illegal purposes ......................................................... 13 Name of the medicinal product ................................................................................... 13 Newly identified signal ............................................................................................... 13 Non-interventional trial; synonym: Non-interventional study .......................................... 14 Occupational exposure to a medicinal product .............................................................. 14 Off-label use ............................................................................................................ 14 Ongoing clinical trial .................................................................................................. 15 Ongoing signal ......................................................................................................... 15 Overdose ................................................................................................................. 15 Package leaflet ......................................................................................................... 15 Periodic safety update report (PSUR)........................................................................... 15 Pharmacovigilance .................................................................................................... 15 Pharmacovigilance system ......................................................................................... 16 Pharmacovigilance system master file (PSMF) .............................................................. 16 Post-authorisation safety study (PASS) ........................................................................ 16 Potential risk ............................................................................................................ 16 Quality adherence ..................................................................................................... 16 Quality assurance ..................................................................................................... 17 Quality control and assurance..................................................................................... 17 Quality improvements ............................................................................................... 17 Quality of a pharmacovigilance system ........................................................................ 17 Quality objectives ..................................................................................................... 17 Quality planning ....................................................................................................... 17 Quality requirements ................................................................................................. 17 Quality system of a pharmacovigilance system ............................................................. 17 Reference safety information ...................................................................................... 18 Registry................................................................................................................... 18 Risk-benefit balance .................................................................................................. 18 Risk management plan (RMP)..................................................................................... 18 Risk management system .......................................................................................... 18 Risk minimisation activity; synonym: Risk minimisation measure.................................... 18 Risks related to use of a medicinal product................................................................... 19 Safety concern ......................................................................................................... 19 Serious adverse reaction............................................................................................ 19 Signal...................................................................................................................... 19 Signal management process....................................................................................... 20 Signal validation ....................................................................................................... 20 Solicited sources of individual case safety reports ......................................................... 20 Spontaneous report, synonym: Spontaneous notification ............................................... 20 Stimulated reporting ................................................................................................. 20 Substance ................................................................................................................ 21

Guideline on good pharmacovigilance practices (GVP) ? Annex I (Rev 3) EMA/876333/2011 Rev 3 (superseded version)

Page 3/24

Summary of product characteristics (SmPC)................................................................. 21 Target population (treatment); synonym: Treatment target population ........................... 21 Target population (vaccine); synonym: Vaccine target population ................................... 21 Traditional herbal medicinal product ............................................................................ 21 Unexpected adverse reaction...................................................................................... 22 Upper management .................................................................................................. 22 Vaccination .............................................................................................................. 22 Vaccination failure .................................................................................................... 22 Vaccine.................................................................................................................... 22 Vaccine failure .......................................................................................................... 22 Vaccine pharmacovigilance......................................................................................... 23 Vaccine product-related reaction................................................................................. 23 Vaccine quality defect-related reaction ........................................................................ 24 Valid individual case safety report ............................................................................... 24 Validated signal ........................................................................................................ 24

Guideline on good pharmacovigilance practices (GVP) ? Annex I (Rev 3) EMA/876333/2011 Rev 3 (superseded version)

Page 4/24

Abuse of a medicinal product

Persistent or sporadic, intentional excessive use of medicinal products which is accompanied by harmful physical or psychological effects [DIR 2001/83/EC Art 1(16)].

Advanced therapy medicinal product (ATMP)

A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2077 Art 1(1)].

Adverse event (AE); synonym: Adverse experience

Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment [Dir 2001/20/EC Art 2(m)].

An adverse event can therefore be any unfavourable and unintended sign (e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Adverse event following immunisation (AEFI)

See Vaccine pharmacovigilance, Vaccine product-related reaction, Vaccine quality defect-related reaction, Immunisation error-related reaction, Immunisation anxiety-related reaction

Adverse reaction; synonyms: Adverse drug reaction (ADR), Suspected adverse (drug) reaction, Adverse effect, Undesirable effect

A response to a medicinal product which is noxious and unintended [DIR 2001/83/EC Art 1(11)]1.

Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility (see Annex IV, ICH-E2A Guideline).

Adverse reactions may arise from use of the product within or outside the terms of the marketing authorisation or from occupational exposure [DIR 2001/83/EC Art 101(1)]. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse, abuse and medication errors. See also Adverse event, Serious adverse reaction, Unexpected adverse reaction, Off-label use, Overdose, Misuse of a medicinal product, Abuse of a medicinal product, Occupational exposure to a medicinal product

Audit

A systematic, disciplined, independent and documented process for obtaining audit evidence and evaluating it objectively to determine the extent to which the audit criteria are fulfilled (see ISO 19011 (3.1)2).

Audit finding(s)

Results of the evaluation of the collected audit evidence against audit criteria (see ISO19011 (3.4)3).

1 In the context of clinical trials, an adverse reaction is defined as all untoward and unintended responses to an investigational medicinal product related to any dose administered [Dir 2001/20/EC Art 2(n)]. 2 International Organization for Standardization (ISO);

Guideline on good pharmacovigilance practices (GVP) ? Annex I (Rev 3) EMA/876333/2011 Rev 3 (superseded version)

Page 5/24

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download